K
KKR & Co. Inc.
+ HoldingHTFL
-0.37%
3M Return
$50.905
+1.486 (+2.92%)At close
Loading chart…
- High
- 51.843
- Open
- 48.370
- VWAP
- 50.05
- Volume
- 1.50M
- Mkt Cap
- —
- Low
- 47.390
- Amount
- 75.27M
- EV/EBITDA, TTM
- -55.55
Heartflow, Inc. is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). Its novel Heartflow Platform uses AI and advanced computational fluid dynamics to create a personalized 3D model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Heartflow RoadMap Analysis, Heartflow FFRCT Analysis, Heartflow Plaque Analysis and Heartflow PCI Navigator. Its Heartflow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. Heartflow RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review. Heartflow FFRCT Analysis calculates blood flow and pinpoints clinically significant CAD.
AI analysis of Heartflow Inc (HTFL)
BuyHeartFlow Inc is a good buy right now due to its current price of $49.74, a significant year-to-date change of +71.69%, and a gross margin that has improved to 83% in Q2 2026. The main risk is the negative net income, which stands at -24.57% for the latest quarter, indicating ongoing losses.
Valuation Metrics
The current forward P/E ratio for Heartflow Inc (HTFL) is 0.00, compared to its 5-year average forward P/E of -53.73.
Whales holding HTFL
Events Timeline
News
5.009-15FoolHeartFlow CEO Sells Shares for $1.8 Million Amid Strong Market Performance
5.009-06FoolHeartFlow CFO Sells Shares Worth $1.7 Million Amid Stock Surge
5.009-06NASDAQ.COMHeartFlow CFO Sells Shares Worth $1.7 Million
2.008-28NewsfilterHeartflow Clinical Trial Significantly Reduces Invasive Heart Procedures
2.008-28Yahoo FinanceHeartflow FUSION Trial Significantly Reduces Invasive Heart Procedures
HTFL FAQ — answered by Alphio AI
Heartflow, Inc. is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). Its novel Heartflow Platform uses AI and advanced computational fluid dynamics to create a personalized 3D model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Heartflow RoadMap Analysis, Heartflow FFRCT Analysis, Heartflow Plaque Analysis and Heartflow PCI Navigator. Its Heartflow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. Heartflow RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review. Heartflow FFRCT Analysis calculates blood flow and pinpoints clinically significant CAD. It operates in the Healthcare sector.
HeartFlow Inc is a good buy right now due to its current price of $49.74, a significant year-to-date change of +71.69%, and a gross margin that has improved to 83% in Q2 2026. The main risk is the negative net income, which stands at -24.57% for the latest quarter, indicating ongoing losses.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.